Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
Employees75,000IPOFeb 15, 1995SIC2834HQ126 East Lincoln Avenue, Rahway, NJ, USA, 07065
to
Financials (EUR)
Profitability
Metric
Current
Margins
Gross Margin
74.8%
Operating Margin
34.0%
EBITDA Margin
43.5%
Net Margin
28.1%
OCF Margin
—
FCF Margin
18.8%
Returns on Capital
ROE
36.8%
ROA
14.8%
ROIC
22.4%
ROCE
23.4%
ROC (Greenblatt)
82.2%
3Y ROIIC
14.2%
Consistency
Years Profitable / 10Y
10
Valuation
Metric
Current
Earnings Multiples
P/E (TTM)
15.91
Forward P/E
22.57
P/E ex-NRI
12.91
Shiller P/E (CAPE)
27.53
Cash Flow Multiples
P/FCF
23.44
P/OCF
17.60
P/Owner Earnings
23.42
FCF Yield
4.32%
Enterprise Value Multiples
EV / EBIT
14.32
EV / Forward EBIT
17.74
EV / EBITDA
11.36
EV / Forward EBITDA
14.57
EV / Revenue
4.94
EV / Forward Revenue
4.79
Asset / Sales
P/S
4.46
P/B
5.45
P/Tangible Book
65.94
Growth-Adjusted
PEG
0.82
Capital Returns
Metric
Current
Dividends
Dividend Yield (TTM)
2.89%
Forward Dividend Yield
2.91%
3Y Dividend Growth
5.4%
Payout Ratio
0.37
5Y Yield on Cost
3.79%
Buybacks & Dilution
3Y Buyback Ratio
0.80%
5Y Share Change
−1.3%
Combined
Shareholder Yield
3.41%
Balance Sheet
Metric
Current
Leverage
Debt / Equity
0.94
Gross Debt / EBITDA
1.75
Cash / Debt
0.30
Equity / Assets
0.38
Coverage
Interest Coverage
16.30
Short-Term Liquidity
Current Ratio
1.54
Quick Ratio
1.30
Cash Ratio
0.51
Composite Scores
Piotroski F-Score
4
Altman Z-Score
3.94
Split History
Date
Split
No split history found.
Ex-date
Amount
Pay date
2026-03-16
$0.85
2026-04-07
2025-12-15
$0.85
2026-01-08
2025-09-15
$0.81
2025-10-07
2025-06-16
$0.81
2025-07-08
2025-03-17
$0.81
2025-04-07
2024-12-16
$0.81
2025-01-08
2024-09-16
$0.77
2024-10-07
2024-06-17
$0.77
2024-07-08
2024-03-14
$0.77
2024-04-05
2023-12-14
$0.77
2024-01-08
10 of 66
View allDate
Transcript
Type
2026-08-04
Q2 2026 Merck & Co Inc Earnings Call Transcript
Earnings Call
2026-08-03
Merck & Co Inc at Investor Event at AIDS Transcript
Analyst/Investor Call
2026-06-09
Merck & Co Inc at Goldman Sachs Healthcare Conference Transcript
Conference Presentations
2026-06-04
Merck & Co Inc at Jefferies Global Healthcare Conference in New York Transcript
Conference Presentations
2026-06-01
Merck & Co Inc Investor Event at ASCO Transcript
Analyst/Investor Call
2026-05-26
Merck & Co Inc Annual Shareholders Meeting Transcript
Shareholders and Annual Meetings
2026-04-30
Q1 2026 Merck & Co Inc Earnings Call Transcript
Earnings Call
2026-03-25
Merck & Co Inc to Acquire Terns Pharmaceuticals Inc Transcript
Company Actions
2026-03-03
Merck & Co Inc at TD Cowen Healthcare Conference Transcript
Conference Presentations
2026-02-03
Q4 2025 Merck & Co Inc Earnings Call Transcript
Earnings Call
10 of 103
5-Step DuPont Analysis
ROE %
35.88%
×
×
Net Margin %
28.17%
×
×
Operating Margin %
34.09%
Operating Income
€19.36B
÷
Revenue
€56.79B
×
Tax Burden
0.8664
Net Income
€16.00B
÷
Pretax Income
€18.46B
×
Interest Burden
0.9536
Pretax Income
€18.46B
÷
Operating Income
€19.36B
×
Asset Turnover
0.50
÷
Revenue
€56.79B
÷
Average Total Assets
€114.36B
Begin Total Assets
€111.84B
End Total Assets
€116.88B
×
Equity Multiplier
2.57
÷
Avg Total Assets
€114.36B
÷
Avg Stockholders Equity
€44.58B
Begin Equity
€44.23B
End Equity
€44.93B